TCM
EIDX

Tang Capital Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Tang Capital Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,783
Closed -$217K – 29
2019
Q4 		$217K Buy
+3,783
New +$187K 0.03% 17

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Tang Capital Management's EIDX Position: Q1 2020 in Review

Tang Capital Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2020, closing a stake of 3,783 shares — an estimated $217K sold.

Tang Capital Management first reported a position in EIDX in Q4 2019 and held it in 1 quarter. The position peaked at $217K in Q4 2019. 89 funds tracked by Wall St. Rank hold EIDX as of Q1 2020.

  • Tang Capital Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Tang Capital Management sold 3,783 Eidos Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $217K.
  • Tang Capital Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Tang Capital Management's Eidos Therapeutics, Inc. Common Stock position peaked at $217K in Q4 2019.
  • 89 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Tang Capital Management's 13F filing for Q1 2020, filed 15 May 2020.